Evidence map›Paper›PMID 38491108›Full record

ArticleScientific reports2024

Novel electrochemical platform based on C

Zhang Junping, Wei Zheng, Tang ZhengFang, L I Ji Yue, An PengHang, Zhang Mingli, An Hongzhi

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Zhang JunpingCancer Research Institute, Henan Integrative Medicine Hospital 45000, Zhengzhou, China.
Wei ZhengCancer Research Institute, Henan Integrative Medicine Hospital 45000, Zhengzhou, China. questwz@163.com.
Tang ZhengFangThe First School of Clinical Medicine, Henan University of Chinese Medicine, Zhengzhou, 450004, China.
L I Ji YueThe First School of Clinical Medicine, Henan University of Chinese Medicine, Zhengzhou, 450004, China.
An PengHangThe First School of Clinical Medicine, Henan University of Chinese Medicine, Zhengzhou, 450004, China.
Zhang MingliCancer Research Institute, Henan Integrative Medicine Hospital 45000, Zhengzhou, China. zhang120@126.com.
An HongzhiCancer Research Institute, Henan Integrative Medicine Hospital 45000, Zhengzhou, China. ahz1967@163.com.
Henan Cancer Hospital · CNFirst Affiliated Hospital of Henan University · CN

Funding

National Natural Science Foundation of China 82305349Young and Middle-aged Academic Leaders of Health in Henan Province 2021-025
6 · The paper itself

Abstract

Lung cancer remains the leading cause of cancer mortality worldwide. Small cell lung cancer (SCLC) accounts for 10-15% of cases and has an overall 5-years survival rate of only 15%. Neuron-specific enolase (NSE) has been identified as a useful biomarker for early SCLC diagnosis and therapeutic monitoring. This work reports an electrochemical immunosensing platform based on a graphene-graphitic carbon nitride (g-C

Indexed as

BiomarkersBiosensing TechniquesLung NeoplasmsPhosphopyruvate HydrataseSmall Cell Lung CarcinomaElectrochemical TechniquesGraphiteHumansImmunoassayLimit of DetectionBiomarkersGraphitePhosphopyruvate Hydratase

Identifiers

PMID38491108
PMCPMC10943129
OpenAlexW4392884727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.